Molybdenum-99

Molybdenum-99
Name	Molybdenum-99
Mass number	99
Num neutrons	57
Num protons	42
Abundance	<0.01% (synthetic)
Halflife	65.976 h
Decay mode1	β⁻
Decay product1	Technetium-99m
Parent	Niobium-99
Parent decay	β⁻
Parent2	Molybdenum-100
Parent2 decay	(n,2n)
Parent3	Uranium-235
Parent3 decay	Fission
Mass	98.9077116
Spin	1/2+
Excess energy	−85967
Decay energy1	1.3573
Binding energy	858934

Molybdenum-99. It is a radioactive isotope of the element molybdenum and is of paramount importance in nuclear medicine as the parent nuclide for technetium-99m, the most widely used medical radioisotope in the world. With a half-life of approximately 66 hours, it is produced artificially, primarily through the fission of uranium-235 in research reactors. Its decay product, technetium-99m, is employed in over 40 million diagnostic medical procedures annually, including single-photon emission computed tomography scans for conditions like coronary artery disease and cancer.

Production

The predominant method for its generation is the neutron-induced fission of uranium-235 targets within high-flux research reactors, such as the BR2 reactor in Belgium, the High Flux Reactor in the Netherlands, and the OPAL reactor in Australia. This process yields a mixture of fission products from which it is chemically separated. Alternative production routes are actively being developed to reduce reliance on highly enriched uranium, including neutron capture on molybdenum-98 using reactors like the University of Missouri Research Reactor or via photonuclear reactions using electron accelerators, a method pioneered by facilities like Tri-University Meson Facility.

Medical applications

It serves no direct diagnostic role but is crucial as the generator parent for technetium-99m. Technetium-99m generators, often called technetium cows, allow hospitals to elute the short-lived daughter isotope as the sodium pertechnetate solution. This radiopharmaceutical is then used to label various compounds for imaging the brain, thyroid, lungs, liver, spleen, kidneys, and cardiovascular system. Key procedures include myocardial perfusion imaging for evaluating heart disease and bone scintigraphy for detecting metastasis.

Physical and chemical properties

As an isotope, its physical behavior is defined by its nuclear properties rather than distinct chemistry from stable molybdenum. It decays via beta decay with a maximum energy of 1.3573 MeV. In its purified form for medical use, it is typically processed into a chemical form suitable for loading onto a generator column, often as molybdate ion in a saline solution. The chemical separation from other fission products, like iodine-131 and xenon-133, is a critical step performed at specialized processing facilities such as those operated by Curium and Lantheus.

Decay and daughter products

It decays with a half-life of 65.976 hours almost entirely to the metastable nuclear isomer technetium-99m, which itself has a half-life of 6.01 hours. Technetium-99m decays by isomeric transition, emitting a 140.5 keV gamma ray ideal for medical detection with gamma cameras, and transforms to the long-lived ground state, technetium-99. A very small branch (about 0.0037%) decays directly to technetium-99. The eventual decay chain proceeds from technetium-99 to stable ruthenium-99.

Supply and demand

Global supply has faced significant vulnerabilities due to the aging and unscheduled shutdowns of major production reactors, such as the National Research Universal reactor in Canada and the High Flux Reactor. This has caused severe shortages, impacting medical services worldwide. Demand remains consistently high, driven by the prevalence of diagnostic imaging. Efforts to diversify and secure supply involve international partnerships coordinated by entities like the Nuclear Energy Agency and the development of new production capacity in countries like the United States through projects supported by the Department of Energy.

History and development

Its medical utility was discovered following the development of the technetium-99m generator system by Walter Tucker and Margaret Greene at the Brookhaven National Laboratory in the late 1950s. The first commercial generator was introduced in the 1960s. For decades, production was dominated by a few reactors using highly enriched uranium, raising nuclear proliferation concerns. Major historical suppliers included the Institut Laue-Langevin in France and the South African Nuclear Energy Corporation. Recent history has been defined by efforts to convert to low-enriched uranium targets and establish non-reactor-based production, spurred by initiatives like the American Medical Isotopes Production Act.

Category:Isotopes of molybdenum Category:Medical isotopes Category:Nuclear medicine